MicroRNA Associated with the Invasive Phenotype in Clear Cell Renal Cell Carcinoma: Let-7c-5p Inhibits Proliferation, Migration, and Invasion by Targeting Insulin-like Growth Factor 1 Receptor.

clear cell renal cell cancer (ccRCC) insulin like growth factor 1 receptor (IGF1R) invasion microRNA migration proliferation

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
28 Sep 2022
Historique:
received: 24 08 2022
revised: 22 09 2022
accepted: 25 09 2022
entrez: 27 10 2022
pubmed: 28 10 2022
medline: 28 10 2022
Statut: epublish

Résumé

Differential microRNA (miRNA) expression can portend clear cell renal cell carcinoma (ccRCC) progression. In a previous study, we identified a subset of dysregulated miRNA in small renal masses, pT1 ccRCC (≤5 cm) that are associated with an aggressive phenotype. The present study investigated miRNA expression in clinical stage I (cT1) tumors (≤5 cm), comparing pathologic stage I (pT1) tumors to those upstaged to pathologic stage 3 (pT3) after surgery following identification of renal vein invasion or invasion into adjacent fat tissue within Gerota's fascia. Twenty cT1 tumors were examined in an miRNA screening, 10 pT1 and 10 pT3 tumors. The ccRCC cell lines 786-O and Caki-1 were used to assess the impact of let-7c-5p and its protein target insulin-like growth factor 1 receptor (IGF1R). Cells were transfected with pre-let-7c-5p and assessed through cell proliferation, migration, and invasion assays. IGF1R expression was evaluated through Simple Western, and interaction between let-7c-5p and IGF1R was confirmed via luciferase reporter assay. Screening identified 20 miRNA, including let-7c-5p, that were dysregulated between pT1 and pT3 upstaged tumors. This miRNA was also downregulated in our previous study of pT1 tumors that progressed to metastatic disease. Transfection of ccRCC cells with pre-let-7c-5p significantly inhibited proliferation, migration, invasion, and IGF1R expression. These findings suggest that miRNA dysregulation is involved in ccRCC progression, specifically through invasion, and that let-7c-5p downregulation contributes to the aggressiveness of small ccRCC tumors, in part, through its regulation of IGF1R.

Identifiants

pubmed: 36289686
pii: biomedicines10102425
doi: 10.3390/biomedicines10102425
pmc: PMC9598558
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : R.K. Mellon Family Foundation
ID : n/a
Organisme : Thea Post Foundation
ID : n/a
Organisme : Morton E. Goulder Research Endowment Fund
ID : n/a

Références

Curr Genomics. 2010 Nov;11(7):537-61
pubmed: 21532838
Clin Chem. 2011 Jul;57(7):954-68
pubmed: 21632885
Sci Rep. 2016 Nov 11;6:36922
pubmed: 27833148
BMC Cancer. 2016 Jul 12;16:453
pubmed: 27405474
Biomed Res Int. 2020 Feb 13;2020:2527643
pubmed: 32104684
J Proteomics. 2013 Dec 06;94:473-85
pubmed: 24332065
Mol Cancer. 2016 Dec 19;15(1):83
pubmed: 27993170
Cytokine Growth Factor Rev. 2017 Apr;34:67-72
pubmed: 28190785
Invasion Metastasis. 1998;18(1):1-14
pubmed: 10207246
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Nucleic Acids Res. 2015 Jul 1;43(W1):W460-6
pubmed: 25977294
Front Endocrinol (Lausanne). 2015 Jul 03;6:106
pubmed: 26191041
Int J Cancer. 2014 Jan 15;134(2):306-18
pubmed: 23825028
Mol Cancer Res. 2020 Jun;18(6):903-912
pubmed: 32169891
Genes Cancer. 2017 May;8(5-6):566-576
pubmed: 28740575
Oncogene. 2007 Oct 4;26(45):6499-508
pubmed: 17486080
Cancer Lett. 2014 Jan 1;342(1):43-51
pubmed: 23981581
World J Surg Oncol. 2015 May 08;13:175
pubmed: 25951903
BMC Cancer. 2014 Jan 02;14:1
pubmed: 24383403
Urol Oncol. 2020 Oct;38(10):799.e11-799.e22
pubmed: 32534961
Bioinformatics. 2012 Aug 1;28(15):2062-3
pubmed: 22718787
Oncogene. 2009 Nov 12;28(45):4034-40
pubmed: 19749800
Semin Cancer Biol. 2020 Oct;65:51-64
pubmed: 31874279
Biochem Med (Zagreb). 2017 Jun 15;27(2):411-417
pubmed: 28694731
Genes Chromosomes Cancer. 2012 Jul;51(7):707-16
pubmed: 22492545
J Clin Oncol. 2002 May 1;20(9):2376-81
pubmed: 11981011
Cell Tissue Res. 2010 Jan;339(1):111-20
pubmed: 19722108
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Cell Mol Life Sci. 2014 Jul;71(13):2403-27
pubmed: 24276851
Cancer Biomark. 2010;9(1-6):461-73
pubmed: 22112490
PLoS One. 2012;7(3):e32832
pubmed: 22479342
Hum Pathol. 2004 Sep;35(9):1132-6
pubmed: 15343516
Nucleic Acids Res. 2020 Jan 8;48(D1):D127-D131
pubmed: 31504780
Nucleic Acids Res. 2012 Dec;40(22):11673-83
pubmed: 23034802
J Cancer. 2019 Aug 27;10(20):4998-5006
pubmed: 31598172
Clin Cancer Res. 2017 May 1;23(9):2245-2254
pubmed: 27799248
Sci Rep. 2017 Aug 29;7(1):9846
pubmed: 28852123
J Cancer. 2018 Jul 30;9(16):2953-2962
pubmed: 30123364
Mol Cancer Ther. 2009 Jun;8(6):1448-59
pubmed: 19509240
J Urol. 2003 Aug;170(2 Pt 1):420-4
pubmed: 12853790
Exp Mol Med. 2018 Apr 13;50(4):1-14
pubmed: 29650947
Mol Cancer. 2014 Sep 06;13:206
pubmed: 25193015
Mol Ther. 2011 Jun;19(6):1116-22
pubmed: 21427705
Neoplasma. 2016;63(5):717-25
pubmed: 27468875
J Natl Cancer Inst. 2006 Sep 20;98(18):1331-4
pubmed: 16985252
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2058-2064
pubmed: 31126198
PLoS One. 2016 Jun 23;11(6):e0157801
pubmed: 27336447
World J Urol. 2011 Jun;29(3):367-73
pubmed: 21229250
Ann Oncol. 2019 May 1;30(5):706-720
pubmed: 30788497
Oncotarget. 2017 Nov 18;8(64):107530-107542
pubmed: 29296184
Biomed Res Int. 2014;2014:742417
pubmed: 24724096
PLoS One. 2012;7(3):e33729
pubmed: 22442719
Oncotarget. 2018 Jan 2;9(10):8927-8940
pubmed: 29507664
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W169-73
pubmed: 23680784
Oncotarget. 2015 Mar 10;6(7):4757-72
pubmed: 25749031
Oncol Lett. 2016 Sep;12(3):1729-1736
pubmed: 27602107
Cancer Res. 2010 Aug 15;70(16):6412-9
pubmed: 20710042
Clin Biochem. 2013 Jul;46(10-11):879-900
pubmed: 23518312
Genome Biol. 2019 Jan 22;20(1):18
pubmed: 30670076
Elife. 2015 Aug 12;4:
pubmed: 26267216

Auteurs

Thomas J Kalantzakos (TJ)

Department of Translational Research, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.

Luke E Sebel (LE)

Department of Urology, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.

James Trussler (J)

Department of Urology, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.

Travis B Sullivan (TB)

Department of Translational Research, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.

Eric J Burks (EJ)

Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA 02118, USA.

Carmen D Sarita-Reyes (CD)

Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA 02118, USA.

David Canes (D)

Department of Urology, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.

Alireza Moinzadeh (A)

Department of Urology, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.

Kimberly M Rieger-Christ (KM)

Department of Translational Research, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.
Department of Urology, Lahey Hospital & Medical Center, Burlington, MA 01805, USA.

Classifications MeSH